Physician profile
Whitney Dawn Johnson
NPI 1871575241
$2,584.80
in general payments reported to CMS, 2019-2025
25 companies · $884 in 2025
The $884 reported for 2025 was more than what 92% of General Practice (Registered Nurse) providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $502 · 2023: $583 · 2024: $223 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.15 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.95 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $434.05 | 2022-2025 | |
| Exeltis, USA INC. | $285.67 | 2021-2025 | Slynd, Twirla |
| Astellas Pharma US INC | $257.63 | 2023-2025 | Veozah |
| Dexcom, INC. | $166.51 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Millicent US INC | $122.84 | 2022-2025 | Intrarosa, Femlyv |
| Myovant Sciences INC. | $79.72 | 2021-2022 | |
| Shield Therapeutics INC | $76.73 | 2024-2025 | |
| Agile Therapeutics, INC. | $59.34 | 2021-2022 | |
| Biogen, INC. | $56.06 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $55.88 | 2021-2022 | |
| Evofem Biosciences, INC. | $47.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $44.21 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.88 | 2022-2023 | |
| Axonics, INC. | $42.46 | 2023 | Bulkamid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.64 | 2024 | |
| Virtus Pharmaceuticals LLC | $40.75 | 2022 | |
| Exact Sciences Corporation | $29.40 | 2025 | The Cologuard Plus Collection Kit |
| Endo Pharmaceuticals INC. | $27.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.55 | 2023 | Vpriv |
| Pacira Pharmaceuticals Incorporated | $23.55 | 2025 | Exparel |
| Merck Sharp & Dohme LLC | $20.43 | 2021 | |
| Bausch Health US, LLC | $17.94 | 2021 | |
| Avion Pharmaceuticals | $14.82 | 2022 | |
| Channel Medsystems, INC. | $12.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.